The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kyriakidis, 2021, SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates, NPJ Vaccines, 6, 28, 10.1038/s41541-021-00292-w
Mohammadi, 2020, Novel coronavirus (COVID-19) overview, J Public Health, 1
Zamani, 2021, Systemic lupus erythematosus manifestation following COVID-19: a case report, J Med Case Rep, 15, 29, 10.1186/s13256-020-02582-8
Mercatelli, 2020, Geographic and Genomic Distribution of SARS-CoV-2 Mutations, Front Microbiol, 11, 1, 10.3389/fmicb.2020.01800
Kouhsari, 2021, Clinical, epidemiological, laboratory, and radiological characteristics of novel Coronavirus (2019-nCoV) in retrospective studies: a systemic review and meta-analysis, Indian J Med Microbiol, 39, 104, 10.1016/j.ijmmb.2020.10.004
Guruprasad, 2021, Bioinformatics. Human SARS CoV‐2 spike protein mutations, Proteins, 89, 569, 10.1002/prot.26042
Khailany, 2020, Genomic characterization of a novel SARS-CoV-2, Gene Rep, 19
Arya, 2021, Structural insights into SARS-CoV-2 proteins, J Mol Biol, 433, 10.1016/j.jmb.2020.11.024
Yurkovetskiy, 2020, Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant, Cell, 183, 739, 10.1016/j.cell.2020.09.032
Xie, 2020, Spike proteins of SARS-CoV and SARS-CoV-2 utilize different mechanisms to bind with human ACE2, Front Mol Biosci, 7, 392, 10.3389/fmolb.2020.591873
Huang, 2020, Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19, Acta Pharmacol Sin, 41, 1141, 10.1038/s41401-020-0485-4
Li, 2016, Structure, function, and evolution of coronavirus spike proteins, Annu Rev Virol, 3, 237, 10.1146/annurev-virology-110615-042301
Walls, 2020, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell, 181, 281, 10.1016/j.cell.2020.02.058
Cai, 2020, Distinct conformational states of SARS-CoV-2 spike protein, Science, 369, 1586, 10.1126/science.abd4251
Hussain, 2020, Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein, J Med Virol, 92, 1580, 10.1002/jmv.25832
Salvatori, 2020, SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines, J Transl Med, 18, 1, 10.1186/s12967-020-02392-y
Samrat, 2020, Li HJVr. Prospect of SARS-CoV-2 spike protein: potential role in vaccine and therapeutic development, Virus Res, 198141, 10.1016/j.virusres.2020.198141
Duan, 2020, The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens, Front Immunol, 11, 2593, 10.3389/fimmu.2020.576622
Suzuki, 2021, SARS-CoV-2 spike protein elicits cell signaling in human host cells: implications for possible consequences of COVID-19 vaccines, Vaccines, 9, 36, 10.3390/vaccines9010036
Berger, 2020, Schaffitzel CJCr. The SARS-CoV-2 spike protein: balancing stability and infectivity, Cell Res, 30, 1059, 10.1038/s41422-020-00430-4
Guruprasad, 2020, Evolutionary relationships and sequence-structure determinants in human SARS coronavirus-2 spike proteins for host receptor recognition, Proteins, 88, 1387, 10.1002/prot.25967
Jackson, 2021, Functional importance of the D614G mutation in the SARS-CoV-2 spike protein, Biochem Biophys Res Commun, 538, 108, 10.1016/j.bbrc.2020.11.026
Wang, 2021, SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen, J Med Virol, 93, 892, 10.1002/jmv.26320
Khalaj-Hedayati, 2020, Protective immunity against SARS subunit vaccine candidates based on spike protein: lessons for Coronavirus vaccine development, J Immunol Res, 2020, 10.1155/2020/7201752
Malik, 2021, Targets and strategies for vaccine development against SARS-CoV-2, Biomed Pharmacother., 137, 111254, 10.1016/j.biopha.2021.111254
Dar, 2020, Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An In Silico Analysis, J Immunol Res, 2020, 8893483, 10.1155/2020/8893483
Yang, 2021, Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials, Lancet Infect Dis, 21, 1, 10.1016/S1473-3099(21)00127-4
Forni, 2021, COVID-19 vaccines: where we stand and challenges ahead, Cell Death Diff, 28, 626, 10.1038/s41418-020-00720-9
Mahase, 2021, Covid-19: novavax vaccine efficacy is 86% against UK variant and 60% against South African variant, BMJ, 372, n296, 10.1136/bmj.n296
Callaway, 2021, Novavax offers first evidence that COVID vaccines protect people against variants, Nature, 590, 17, 10.1038/d41586-021-00268-9
Chang-Monteagudo, 2021, A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. a preliminary report of an open-label phase 1 clinical trial, medRxiv
Zhang, 2020, Progress and prospects on vaccine development against SARS-CoV-2, Vaccines, 8, 10.3390/vaccines8020153
Liang, 2020, Adjuvants for coronavirus vaccines.Front, Immunol, 11, 2896
Bettini, 2021, SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond, Vaccines, 9, 147, 10.3390/vaccines9020147
Azkur, 2020, Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19, Allergy, 75, 1564, 10.1111/all.14364
Peng, 2020, Particulate Alum via Pickering Emulsion for an Enhanced COVID‐19 Vaccine Adjuvant, Adv Mater, 32
Adney, 2019, Efficacy of an adjuvanted middle east respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas, Viruses, 11, 10.3390/v11030212
Kuo, 2020, Development of CpG-adjuvanted stable pre-fusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19, Sci Rep, 10, 1, 10.1038/s41598-020-77077-z
Shi, 2019, Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity, Vaccine, 37, 3167, 10.1016/j.vaccine.2019.04.055
Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, et al. SARS-CoV-2 variant B. 1.1. 7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. Cell Host Microbe. 2021.14;29(4):529-539.
Altmann, 2021, Immunity to SARS-CoV-2 variants of concern, Science, 371, 1103, 10.1126/science.abg7404
Rees-Spear, 2021, The impact of spike mutations on SARS-CoV-2 neutralization, bioRxiv
Hu, 2021, Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies, Cell Mol Immunol, 18, 1061, 10.1038/s41423-021-00648-1
Wang, 2021, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature, 593, 130, 10.1038/s41586-021-03398-2
Cherian, 2021, Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India, bioRxiv
Gómez, 2021, Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19, Vaccines, 9, 243, 10.3390/vaccines9030243
Kumar, 2021, Possible link between higher transmissibility of B.1.617 and B.1.1.7 variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity, bioRxiv
Planas, 2021, Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies, Nat Med, 27, 917, 10.1038/s41591-021-01318-5
Singh, 2021, Structure-function analyses of new SARS-CoV-2 variants B. 1.1. 7, B. 1.351 and B. 1.1. 28.1: clinical, diagnostic, Therap Public Health Implic, 13, 439
Wang, 2021, Susceptibility of circulating SARS-CoV-2 variants to neutralization, N Engl J Med, 384, 2354, 10.1056/NEJMc2103022
Koyama, 2020, Variant analysis of SARS-CoV-2 genomes, Bull World Health Organ, 98, 495, 10.2471/BLT.20.253591
Gupta, 2021, Will SARS-CoV-2 variants of concern affect the promise of vaccines?, Nat Rev Immunol, 21, 340, 10.1038/s41577-021-00556-5
Slavov, 2021, Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 lineage (20H/501Y.V2) in Brazil, J Med Virol, 10.1002/jmv.27190
Mallm, 2021, Local emergence and decline of a SARS-CoV-2 variant with mutations L452R and N501Y in the spike protein, medRxiv
Volz, 2021, Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity, Cell, 184, 64, 10.1016/j.cell.2020.11.020
Hoffmann, 2021, SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies, Cell, 184, 2384, 10.1016/j.cell.2021.03.036
Moyo-Gwete, 2021, SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies, bioRxiv
Zhou, 2021, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera, Cell, 184, 2348, 10.1016/j.cell.2021.02.037
Rees-Spear, 2021, The effect of spike mutations on SARS-CoV-2 neutralization, Cell Rep, 34, 10.1016/j.celrep.2021.108890
Shen, 2021, Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351, N Engl J Med, 384, 2352, 10.1056/NEJMc2103740
Shinde, 2021, Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant, N Engl J Med, 1384, 1899, 10.1056/NEJMoa2103055
Wibmer, 2021, SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma, Nat Med, 27, 622, 10.1038/s41591-021-01285-x
Hoffmann, 2021, SARS-CoV-2 variants B.1.351 and B.1.1.248: escape from therapeutic antibodies and antibodies induced by infection and vaccination, bioRxiv
Focosi, 2021, Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based Covid-19 therapeutics and vaccines, Rev Med Virol, 10.1002/rmv.2231
Fontanet, 2021, SARS-CoV-2 variants and ending the COVID-19 pandemic, Lancet, 397, 952, 10.1016/S0140-6736(21)00370-6
Davis, 2021, Reduced neutralization of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination, Nature, 596, 276, 10.1038/s41586-021-03777-9
Lazarevic, 2021, Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far?, Viruses, 13, 10.3390/v13071192
Lustig, 2021, Neutralizing capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel, 26
Kupferschmidt, 2021, Delta variant triggers new phase in the pandemic, Science, 372, 1375, 10.1126/science.372.6549.1375
Romero, 2021, The emergence of SARS-CoV-2 variant lambda (C.37) in South America, medRxiv
Tada, 2021, SARS-CoV-2 lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum, bioRxiv
Acevedo, 2021, Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda, medRxiv
Weisblum, 2020, Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants, Elife, 9, 10.7554/eLife.61312
Chen, 2021, Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies, Nat Med, 27, 717, 10.1038/s41591-021-01294-w
Xie, 2021, Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera, Nat Med, 27, 620, 10.1038/s41591-021-01270-4
Collier, 2021, Impact of SARS-CoV-2 B. 1.1. 7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2, medRxiv
Wu, 2021, mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants, bioRxiv
Garcia-Beltran, 2021, Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, Cell, 184, 2372, 10.1016/j.cell.2021.03.013
2021, Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2 B.1.617.2 Delta variant emergence, replication and sensitivity to neutralising antibodies, bioRxiv